---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-21-000062"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:18:45.037636+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q3 net revenues up 34% YoY to $112.2M; GAAP EPS $0.59 vs $0.08

## Summary
- Net revenues $112.2M (Q3 2021), up 34% from $83.4M in Q3 2020.
- GAAP net income $29.5M ($0.59 diluted EPS) vs $3.9M ($0.08) a year ago.
- Adjusted non-GAAP net income $23.0M ($0.46 EPS) vs $7.6M ($0.15).
- Growth driven by glucagon, Primatene Mist, epinephrine; CEO expects pipeline approvals in 2022.
- Nine-month net revenues $316.9M, up 25% YoY; GAAP net income $42.4M.

## SEC filing metadata
- accession: 0001297184-21-000062
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718421000062/0001297184-21-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718421000062/amph-20211108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-21-000062
- JSON: https://secwatch.observer/filing/0001297184-21-000062.json
- Plain text: https://secwatch.observer/filing/0001297184-21-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.